Oncobiomix

Harnessing the power of the microbiome.

Learn More

1 in 8 men will get prostate cancer

Prostate cancer continues to be the most frequently diagnosed cancer in men, and despite numerous advancements, it remains the second leading cause of cancer-related deaths1. Unhealthy gut microbiota may have a negative impact on your cancer risk.2 Previous research has shown microbiota may cause subtle inflammation starting your colon, leading to immune changes and metabolite production, in turn, influencing your risk of cancer.3,4

The importance of the microbiome

10-100 Trillion Symbiotic microbial cells, primarily bacteria, are harbored in the gut.

3.3 Million Non-redundant genes in the human gut microbiome.

>10,000 Different identified microbe species living in the human body.

99.9% Of individuals are identical to one another in terms of host genome.

80-90% Of individuals are different from one another in terms of the microbiome.

Studies demonstrate that microbiota can affect cancer susceptibility and progression such as modulating inflammation, inducing DNA damage, and producing metabolites involved in oncogenesis or tumor suppression.5

Microbiome signatures Microbiome signatures have been linked as indicators of health6

Oncobiomix aims to investigate the microbiome and its application as a “biosensor”.7

Microbiome signatures <span src=Microbiome signatures have been linked as indicators of health6">

Diet and pre-biotics

Non-digestible fibers that induce a shift in the gut microbiota composition

Probiotics

Live microorganisms that confer health benefit to the host

Postbiotics

Well-defined mixtures of single molecules produced by bacteria with demonstrated benefit for the host

Bacteria Consortia

Rationally designed consortia of commensal bacteria

Fecal Microbiota Transplant

Transfer of fecal material from an individual (donor) into another individual (recipient)

Microbiome Analysis

  • 1
    Collect sample & transfer it into provided solution
  • 2
    Return to Oncobiomix Affiliated Laboratory
  • 3
    Lab extracts microbe DNA
  • 4
    AI model
  • 5
    Report

About Oncobiomix

Oncobiomix Inc. is incorporated in Delaware and based in San Antonio, Texas. We are interested in investigating the application of microbiomes as biosensors. Our team has worked on various applications of the microbiome for over 10 years.

Our cutting-edge technology has been the culmination of ten years of intensive research, dedication, and drive.

About Oncobiomix

Interested in learning more?

Get Notified of Updates

We will alert you of any noteworthy news and regulatory approvals.

Until then, we encourage you to sign up for the clinical trial which is voluntary and only for research use but will help bring the test to the market.

Research Study

Contact Us

Do you have questions regarding Oncobiomix? Reach out via the form below.

References

  1. Siegel RL , Giaquinto AN , Jemal A . Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1): 12-49. doi:10.3322/caac.21820
  2. Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M, Kroemer G. Cancer and the gut microbiota: an unexpected link. Sci Transl Med. 2015 Jan 21;7(271):271ps1. doi: 10.1126/scitranslmed.3010473. PMID: 25609166; PMCID: PMC4690201.
  3. Liss MA, White JR, Goros M, Gelfond J, Leach R, Johnson-Pais T, Lai Z, Rourke E, Basler J, Ankerst D, Shah DP. Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer. Eur Urol. 2018 Nov;74(5):575-582. doi: 10.1016/j.eururo.2018.06.033. Epub 2018 Jul 12. PMID: 30007819; PMCID: PMC6716160.
  4. Wheeler KM, Liss MA. The Microbiome and Prostate Cancer Risk. Curr Urol Rep. 2019 Sep 7;20(10):66. doi: 10.1007/s11934-019-0922-4. PMID: 31493090.
  5. Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017 Jul 8;67(4):326-344. doi: 10.3322/caac.21398. Epub 2017 May 8. PMID: 28481406; PMCID: PMC5530583.
  6. Wu G, Xu T, Zhao N, Lam YY, Ding X, Wei D, Fan J, Shi Y, Li X, Li M, Ji S, Wang X, Fu H, Zhang F, Shi Y, Zhang C, Peng Y, Zhao L. A core microbiome signature as an indicator of health. Cell. 2024 Oct 7:S0092-8674(24)01038-9. doi: 10.1016/j.cell.2024.09.019. Epub ahead of print. PMID: 39378879.
  7. Sosnowski K, Akarapipad P, Yoon J-Y. The future of microbiome analysis: Biosensor methods for big data collection and clinical diagnostics. Med Devices Sens. 2020; 3:e10085. https://doi.org/10.1002/mds3.10085